Professorship for Medical Biometry with Focus on Clinical Epidemiology

The professorship focuses on methological and biostatistical aspects of clinical research. We deal with deriving answerable clinical questions, developing study design and framework, supervising the progress of clinical trials with biostatistical methods, statistical analysis and communication of results. We investigate own research questions in clinical epidemiology and methodological issues related to dealing with systematic bias and statistical uncertainty.

Lead

Eva Hoster
Univ. Prof. Dr. rer. biol. hum., Dipl.-Math. Eva Hoster

Head of Professorship of Medical Biometry with a focus on Clinical Epidemiology

Team

Name Title Position
Gutmair, Katja M.Sc. Scientific reseacher
Jiang, Linmiao Dr. Scientific researcher
Jurinovic, Vindi Dr. rer. biol. hum. Dipl.-Math. Guest researcher

Research area and projects

Biometry of clinical trials: design and sample size determination for clinical phase 2 and phase 3 trials, especially in oncology, cardiology, and pediatrics

  • Operationalization of the scientific question
  • Optimization of trial design
  • Definition of the statistical design
  • Sample size determination
  • Planning of interim analyses

  • Long-term follow-up of clinical trials
  • Cross-trial comparisons
  • Impact of rituximab maintenance for younger patients with mantle cell lymphoma without and with ibrutinib-containing first-line treatment
  • Estimation of conditional survival of patients with mantle cell lymphoma
  • Impact of different coding variants on frequency estimation for adverse events
  • Long-term trends in clinical outcome for patients with mantle cell lymphoma treated in prospective trials

  • MULTIlayer Predictive models for relapsed MCL after ibrutinib as first Line therapY (MULTIPLY) in the EuMCLNetwork TRIANGLE phase III trial
  • Impact of minimal residual disease (MRD) for estimating prognosis and treatment evaluation or modification in follicular and mantle cell lymphoma
  • Prognostic value of histopathological markers in follicular and mantle cell lymphoma
  • Clinico-prognostic models for follicular and mantle cell lymphoma
  • "Use case indolent lymphoma“ as part of DIFUTURE

  • New method to estimate clinical outcomes from clinical trials with two-stage randomization
  • Comparison of methods to evaluate estimands for treatment effects on overall survival considering subsequent therapies
  • Comparison of statistical tests of hypotheses on time-to-event endpoints with fixed time point and stratification
  • Evaluation of statistical designs in current oncological phase 2 clinical trials

  • Enabling reuse of data from terminated clinical trials of the German Lymphoma Alliance (GLA) for further clinical and translational research

Biometry of Clinical Trials: Research on treatment primarily of haematological malignancies

Trial NameSponsorDiseaseIndicationPhaseIdentifier
European MCL 1not applicablemantle cell Lymphomafirst-line3not applicable
European MCL Youngernot applicablemantle cell Lymphomafirst-line3NCT00209222
European MCL Elderlynot applicablemantle cell Lymphomafirst-line3NCT00209209
OSHO#70Klinikum der Universität Münchenfollicular lymphomafirst-line32005-005473-29 (EudraCT)
TRIANGLEKlinikum der Universität Münchenmantle cell Lymphomafirst-line32014-001363-12 (EudraCT)
MCL R2 ElderlyLysarc, Francemantle cell Lymphomafirst-line32012-002542-20 (EudraCT)
R-HADKlinikum der Universität Münchenmantle cell Lymphomarelapsed or refractory32005-005144-62 (EudraCT)
ALTERNATIVEKlinikum der Universität Münchenfollicular lymphomafirst-line22014-005164-15 (EudraCT)
ALTERNATIVE-CKlinikum der Universität Münchenfollicular lymphomafirst-line22018-004038-13 (EudraCT)
Gabe2016Klinikum der Universität Münchenfollicular lymphomafirst-line32016-000755-27 (EudraCT)
MCL Elderly 3Universitätsmedizin Mainzmantle cell Lymphomafirst-line22020-002935-30 (EudraCT)
EEN-RICHKlinikum der Universität MünchenMorbus Crohnnot applicable1/22022-503027-10-00 (EU CT)
OLYMP-1Universitätsklinikum Ulmmantle cell Lymphomafirst-line or relapsed or refractory22017-003149-56 (EudraCT)
COUP-1Universitätsklinikum Ulmmantle cell Lymphomafirst-line or relapsed or refractory22017-003150-16 (EudraCT)
POLE-1Universitätsklinikum Ulmmantle cell Lymphomafirst-line or relapsed or refractory22018-000187-28 (EudraCT)
CZAR-1Universitätsklinikum UlmWaldenström's macroglobulinemiafirst-line or relapsed or refractory32018-003526-88 (EudraCT)